<DOC>
	<DOCNO>NCT00429442</DOCNO>
	<brief_summary>A Double Blind , Randomised , Placebo Controlled Study Investigating Simvastatin add-on Treatment Copaxone Treatment Relapsing Multiple Sclerosis patient treat Copaxone least 3 month</brief_summary>
	<brief_title>Simvastatin add-on Treatment Copaxone Treatment Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>This double blind , placebo control , randomise , phase 3 study . Patients treat Copaxone least 6 month screen visit randomise treatment simvastatin placebo add-on Copaxone treatment . Patients start treatment 40 mg peroral simvastatin daily ( apparently identical placebo ) one month . Hereafter , patient escalate dosage 80 mg daily . The patient examine clinically screen , baseline 3 , 6 12 month . Blood sample immunology perform baseline 1 , 3 , 6 12 month . Blood sample safety assessment perform study visit . MRI perform ( T1-weighted T2-weighted ) baseline 6 12 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>A patient may include s/he fulfils criterion mention : The patient must give write informed consent prior study related activity . Study related activity procedure would perform normal management patient . Is age 18 60 year ( include ) . Suffers definite relapsingremitting MS accord Poser criterion ( CDMS LSDMS ) 21 definite MS accord McDonald criterion 22 . Has disability equivalent EDSS 6.5 less 20 . Has show clinical activity define least one report documented relapse within last year two report documented relapse within last two year . Has treat Copaxone least 3 month . The patient must prepare consider able follow protocol whole study period attend plan visit , even treatment withdrawn . The patient must include criterion mention fulfil : Any condition might give rise similar symptom MS. Has receive treatment glucocorticoid ACTH later one month prior inclusion study , i.e . screen visit . Has experience onset relapse within one month prior inclusion study , i.e . screen visit . Has suffer major depression . Has receive immunosuppressive treatment 6 month prior screen . Alcohol drug dependency . Has cardiac insufficiency , cardiomyopathy , significant cardiac dysrhythmia , unstable advanced ischemic heart disease ( NYHA III IV ) . Significant hypertension ( BP &gt; 180/110 mmHg ) . Has renal insufficiency define serum creatinine &gt; 1.5 time upper normal reference limit . ASAT and/or ALAT 1.5 time normal upper reference limit . Leucopaenia &lt; 2.5 x 109/L thrombopaenia &lt; 100 x109/L . Any medical illness require treatment systemic corticosteroid . Any systemic disease influence patient 's safety compliance , evaluation disability . Women pregnant , breastfeed possibility pregnancy study . To avoid pregnancy , woman postmenopausal , surgically sterile , sexually inactive practice reliable contraception ( contraceptive pill , intrauterine device , administration deposit progestin , subcutaneous implant , contraception ring , transdermal deposit plaster ) . Known suspect allergy study product relate product . Participation study , involve investigational product , within 30 day prior participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Simvastatin</keyword>
	<keyword>CNS Inflammation</keyword>
	<keyword>Copaxone</keyword>
</DOC>